These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 9846021)

  • 1. Scopolamine butylbromide plus octreotide in unresponsive bowel obstruction.
    Mercadante S
    J Pain Symptom Manage; 1998 Nov; 16(5):278-80. PubMed ID: 9846021
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial.
    Mystakidou K; Tsilika E; Kalaidopoulou O; Chondros K; Georgaki S; Papadimitriou L
    Anticancer Res; 2002; 22(2B):1187-92. PubMed ID: 12168923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer.
    Peng X; Wang P; Li S; Zhang G; Hu S
    World J Surg Oncol; 2015 Feb; 13():50. PubMed ID: 25889313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction.
    Mercadante S; Ripamonti C; Casuccio A; Zecca E; Groff L
    Support Care Cancer; 2000 May; 8(3):188-91. PubMed ID: 10789958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review.
    Mercadante S; Casuccio A; Mangione S
    J Pain Symptom Manage; 2007 Feb; 33(2):217-23. PubMed ID: 17280927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisecretory agents in gastrointestinal obstruction.
    Muir JC; von Gunten CF
    Clin Geriatr Med; 2000 May; 16(2):327-34. PubMed ID: 10783431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Octreotide for malignant bowel obstruction: twenty years after.
    Mercadante S; Porzio G
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):388-92. PubMed ID: 22277783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The challenge of treating malignant bowel obstruction.
    J Support Oncol; 2006 Feb; 4(2):83-4. PubMed ID: 16499129
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of octreotide in malignant bowel obstruction.
    Krammer LM
    Oncol Nurs Forum; 1999 Jun; 26(5):831-2. PubMed ID: 10382174
    [No Abstract]   [Full Text] [Related]  

  • 10. How to use octreotide for malignant bowel obstruction.
    Ripamonti C; Mercadante S
    J Support Oncol; 2004; 2(4):357-64. PubMed ID: 15357519
    [No Abstract]   [Full Text] [Related]  

  • 11. Severe cholinergic urticaria successfully treated with scopolamine butylbromide in addition to antihistamines.
    Ujiie H; Shimizu T; Natsuga K; Arita K; Tomizawa K; Shimizu H
    Clin Exp Dermatol; 2006 Jul; 31(4):588-9. PubMed ID: 16716168
    [No Abstract]   [Full Text] [Related]  

  • 12. Malignant irreversible intestinal obstruction: the powerful association of octreotide to corticosteroids, antiemetics, and analgesics.
    Weber C; Zulian GB
    Am J Hosp Palliat Care; 2009; 26(2):84-8. PubMed ID: 19088264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Octreotide prevents the pathological alterations of bowel obstruction in cancer patients.
    Mercadante S; Avola G; Maddaloni S; Salamone G; Aragona F; Rodolico V
    Support Care Cancer; 1996 Sep; 4(5):393-4. PubMed ID: 8883235
    [No Abstract]   [Full Text] [Related]  

  • 14. [Somatostatin and its analogs in the treatment of gastrointestinal and liver diseases].
    Feu F; Bosch J
    Gastroenterol Hepatol; 1996 Feb; 19(2):68-77. PubMed ID: 8616683
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial.
    Ripamonti C; Mercadante S; Groff L; Zecca E; De Conno F; Casuccio A
    J Pain Symptom Manage; 2000 Jan; 19(1):23-34. PubMed ID: 10687323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of glucagon and scopolamine butylbromide as premedication for colonoscopy in unsedated patients.
    Yoshikawa I; Yamasaki M; Taguchi M; Kanda K; Tashiro M; Kume K; Tabaru A; Otsuki M
    Dis Colon Rectum; 2006 Sep; 49(9):1393-8. PubMed ID: 16699970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Octreotide may prevent definitive intestinal obstruction.
    Mercadante S; Kargar J; Nicolosi G
    J Pain Symptom Manage; 1997 Jun; 13(6):352-5. PubMed ID: 9204656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained release octreotide may have a role in the treatment of malignant bowel obstruction.
    Massacesi C; Galeazzi G
    Palliat Med; 2006 Oct; 20(7):715-6. PubMed ID: 17060271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effective made of octreotide intravenous administration for malignant gastrointestinal obstruction in terminal cancer patients].
    Tanimura K; Onda S; Mitsunobu M
    Gan To Kagaku Ryoho; 2010 Oct; 37(10):1991-3. PubMed ID: 20948271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised clinical trial investigating the effects of combined administration of octreotide and methylglucamine diatrizoate in the older persons with adhesive small bowel obstruction.
    Zhang Y; Gao Y; Ma Q; Dang C; Wei W; De Antoni F; Rocci R; Chen W
    Dig Liver Dis; 2006 Mar; 38(3):188-94. PubMed ID: 16311083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.